ACPE UAN #: 0233-0000-18-003-H01-P
Release Date: April 6, 2018
Expiration Date: April 6, 2021
Activity Type: Knowledge-based
Credit Hours: 1.0 contact hours (0.1 CEU)
Activity Fee: There is no fee to participate in this home study activity.
This home study activity has been designed to meet the educational needs of pharmacists in managed care settings.
Duchenne muscular dystrophy (DMD) is an x-linked genetic disease caused by mutations in the DMD gene that result in the lack of production of the dystrophin protein. The dystrophin protein works to protect muscles from contraction-induced injury. Without dystrophin, children are typically diagnosed with progressive muscle weakness by age 3-6 because they have frequent falling, difficulties in rising from the floor, or experience difficulties in walking and running and may waddle when walking. Most have enlarged calves due to fat accumulation within the muscle. Muscle disease progresses throughout life resulting in loss of ambulation around age 12 and the need for ventilator support by late teen years and often death in the 20’s. With multisystem supportive care, patient lifespan has increased substantially. Currently available treatments can slow the progression of DMD but are not curative. Recently approved and in the pipeline therapies aim to correct and restore dystrophin production, and may further improve patient outcomes and quality of life.
This webinar will aim to provide a stronger understanding of DMD and current care standards, data on the emerging DMD treatments, and an understanding of how these new treatment options may increase a patient’s quality of life and affect formulary decision-making.
At the completion of this activity, participants should be able to:
- Explain the pathophysiology, incidence, and life expectancy for patients with Duchenne muscular dystrophy (DMD).
- Discuss the current recommended care options for DMD patients, including the role of newly approved medications.
- Detail the impact of DMD on a patient’s quality of life and how currently available treatment affects direct and indirect costs of care.
- Identify at least two DMD drugs in the treatment pipeline, how these may increase patient quality of life, and where these may fit into current guidelines.
- Describe factors that could be used for determining formulary placement of DMD drug options.
Schedule of Educational Activity
- DMD Overview and Therapeutic Options | Stanley F. Nelson, MD
Formulary Management Strategies for DMD | Susan Downard, RPh, BSPharm
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live webinar activity on April 6, 2018. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and
As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Statement of Commercial Support
This program Is supported by an educational grant from Sarepta Therapeutics.
Ruby M. Singh, PharmD
Vice President Education and Training
Academy of Managed Care Pharmacy
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-18-003-H01-P||1 Contact Hour||April 06, 2018 - April 06, 2021|